Contura sells Bulkamid® to Axonics Modulation Technologies, Inc Posted on 26 February 2021 | by laura.hedley@contura.com | Leave a Comment on Contura sells Bulkamid® to Axonics Modulation Technologies, Inc
Bulkamid: one year anniversary of FDA approval in the United States Posted on 3 February 2021 | by Originmeister | Leave a Comment on Bulkamid: one year anniversary of FDA approval in the United States
FDA approves Bulkamid® in the United States and is now set for launch in Quarter 1 2020 Posted on 1 January 2020 | by Originmeister | Leave a Comment on FDA approves Bulkamid® in the United States and is now set for launch in Quarter 1 2020
Results of Randomised Controlled Trial of Bulkamid® versus Tension-free Vaginal Tape Published Posted on 1 January 2020 | by Originmeister | Leave a Comment on Results of Randomised Controlled Trial of Bulkamid® versus Tension-free Vaginal Tape Published
Urethral bulking agents to be considered as two distinct classes: particulate and non-particulate Posted on 1 December 2019 | by Originmeister | Leave a Comment on Urethral bulking agents to be considered as two distinct classes: particulate and non-particulate
Observational multicentered study shows that two thirds of women with stress urinary incontinence choose Bulkamid® when offered a choice Posted on 1 December 2019 | by Originmeister | Leave a Comment on Observational multicentered study shows that two thirds of women with stress urinary incontinence choose Bulkamid® when offered a choice
Searchlight Pharma Announces Launch of Bulkamid® for Treatment of Female Stress Urinary Incontinence Posted on 10 May 2018 | by Originmeister | Leave a Comment on Searchlight Pharma Announces Launch of Bulkamid® for Treatment of Female Stress Urinary Incontinence
Contura files Bulkamid PMA Posted on 30 July 2017 | by Originmeister | Leave a Comment on Contura files Bulkamid PMA
Speciality European Pharma signs clinical research agreement with Central Manchester University Hospitals NHS Foundation Trust for the study of Bulkamid as a first line treatment for stress urinary incontinence Posted on 17 February 2017 | by Originmeister | Leave a Comment on Speciality European Pharma signs clinical research agreement with Central Manchester University Hospitals NHS Foundation Trust for the study of Bulkamid as a first line treatment for stress urinary incontinence
Speciality European Pharma extends distribution agreement for Regurin XL in the United Kingdom Posted on 20 December 2016 | by Originmeister | Leave a Comment on Speciality European Pharma extends distribution agreement for Regurin XL in the United Kingdom